Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

Summary

This is a proof of concept, single center study for the donation of HCV-positive kidney to HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of commercially available DAA therapy to prevent HCV transmission upon transplantation.

Timeline

Start

2019-02-15

Primary completion

2020-12-31

Completion

2021-04-15

Outcome

Outcome not reported

Stopped: “did not move forward with IRB approval, competing study”

Drugs

Indications